_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.jpg "ASCO 2023: Latest in PARP inhibitors in prostate cancer from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 10 min 40 sec
✓ Published: 06-Jun-2023
✓ Published: 06-Jun-2023
Description:
Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r
Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_parp-inhibitors-for-metastatic-breast-cancer.webp "Prof Michael Untch speaks to ecancer at ESMO 2019 in Barcelona about some of the trials covering PARP inhibitors for metastatic breast cancer.nnProf Untch outlines the OlympiAD and EMBRACA trials for patients with BRCA mutations, both with positive results.nnHe also touches on the BrighTNess study which involves a new PARP inhibitor, veliparib.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
_dora-using-olaparib-alone-or-with-durvalumab-in-platinum-responsive-advanced-triple-negative-breast-cancer.webp "Dr Tira Tan speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase II DORA study. nnShe explains that the trial uses the PARP inhibitor olaparib alone or in combination with the PD-L1 inhibitor durvalumab to treat patients with platinum responsive advanced triple-negative breast cancer, thereby using a maintenance strategy to reduce the toxicities experienced by patients.nnDr Tan says that they are expecting some correlative work to come out of")
⏲ 2 min 12 sec ✓ 03-Jun-2019
_parp-inhibitors-in-prostate-cancer-and-latest-developments.webp "Prof. Neeraj Agarwal takes a look at poly-ADP ribose polymerase inhibitors (PARPi's) in prostate cancer and in particular the latest clinical developments.")
_metastatic-castration-resistant-prostate-cancer-updates-from-asco-2019.webp "Dr Neal Shore, Dr Joaquin Mateo and Dr Karim Fizazi discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). nnDr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.nnThe session concludes with Dr Mateo")
⏲ 13 min 83 sec ✓ 06-Jun-2019
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.webp "GU CONNECT members, Assoc. Prof. Tanya Dorff (USA) and Prof. Gerhardt Attard (UK) along with guest expert Prof. Fred Saad (Canada) were joined by participants from around the world to discuss targeting advanced prostate cancer with PARP inhibitors: Who, When and How?n nThere was a very interesting and dynamic discussion about:nThe efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour typesnImplementation of testing strategies to")
⏲ 31 min 97 sec ✓ 15-Mar-2022
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.webp "Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r")
_m2-evolving-landscape-of-parp-inhibitors-in-mcrpc-combination-with-anti-androgens.webp "In this video you'll learn about PARP inhibitors in prostate cancer, in particular the rationale behind combination treatment with anti-androgens from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.nnWe are pleased to share that this video is part of a micro learning programme that is endorsed by ZERO Prostate Cancer and EAUN.You can find out more about ZERO at https://zerocancer.org/ and EAUN at https://nurses.uroweb.org/nnThe micro learning programme includes videos")
⏲ 2 min 41 sec ✓ 17-Jan-2023
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.webp "Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.nnThis was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
⏲ 3 min 31 sec ✓ 28-Sep-2019
_parp-inhibitors-for-metastatic-breast-cancer.jpg)
_dora-using-olaparib-alone-or-with-durvalumab-in-platinum-responsive-advanced-triple-negative-breast-cancer.jpg)
_parp-inhibitors-in-prostate-cancer-and-latest-developments.jpg)
_metastatic-castration-resistant-prostate-cancer-updates-from-asco-2019.jpg)
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.jpg)
_m2-evolving-landscape-of-parp-inhibitors-in-mcrpc-combination-with-anti-androgens.jpg)
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.jpg)
![[+]](/images/menu.gif){kind=small}